Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Fatima Amanat(Icahn School of Medicine at Mount Sinai), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Harm van Bakel(Icahn School of Medicine at Mount Sinai), Hala Alshammary(Icahn School of Medicine at Mount Sinai), Ariel Raskin(Icahn School of Medicine at Mount Sinai), Ana S. Gonzalez‐Reiche(Icahn School of Medicine at Mount Sinai), Gagandeep Singh(Icahn School of Medicine at Mount Sinai), Florian Krammer(Icahn School of Medicine at Mount Sinai), Emilia Mia Sordillo(Mount Sinai Health System), Adriana van de Guchte(Icahn School of Medicine at Mount Sinai), Angela A. Amoako(Icahn School of Medicine at Mount Sinai), D. Noah Sather(University of Washington), PARIS study group(Icahn School of Medicine at Mount Sinai)
Cited by 55
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803